

: WALDMANN et al -- Serial No.: 09/125,460

--The present application represents the US national

D¹ phase of PCT/GB97/00472, filed February 20, 1997.--

After page 33, insert the Abstract of the Disclosure submitted herewith on a separate sheet.

IN THE CLAIMS:

Cancel claim 1 without prejudice and add new claim 25 in lieu thereof.

D³ 25. An antibody which is a modified version of a therapeutic antibody with affinity for a cell surface antigen, said antibody having reduced affinity for the antigen compared with the therapeutic antibody as a result of modification or modifications to the antibody, wherein the antibody is capable of inducing immunological tolerance to the therapeutic antibody and wherein the antibody is not a mixed molecule antibody having an H or L chain of the therapeutic antibody paired with an L or H chain of an unrelated antibody, wherein the modification consists of an alteration in at least one of the complementarity determining regions (CDRs), wherein the alteration is achieved by genetic manipulation of a nucleic acid coding

WALDMANN et al -- Serial No.: 09/125,460

D3
for the CDR, and wherein the affinity of the antibody for
the antigen is reduced to less than 50% of the affinity of
the therapeutic antibody.

[Amend the claim 2 as follows.]

D4
2. (Amended) An antibody as claimed in claim 25,
wherein the framework regions of the variable domains of
the antibody have the same or substantially the same amino
acid sequence as the therapeutic antibody framework
regions.

Cancel claims 3-5 without prejudice.

D5
6. (Twice Amended) An antibody as claimed in
Claim 25, wherein the CDRs are foreign with respect to the
constant region of the antibody.

7. (Twice Amended) An antibody as claimed in
Claim 25, wherein the CDRs are foreign with respect to the
heavy and light chain variable domain framework regions.

D6
9. (Twice Amended) An antibody as claimed in
claim 25, wherein the therapeutic antibody has affinity for
CD52.